A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Summary

The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into the bloodstream and how long the body takes to eliminate it. This study will last up to about 19 weeks including screening period.

Timeline

Start

2020-11-23

Primary completion

2021-11-30

Completion

2021-11-30

Publications

• Roell W, Alsina-Fernandez J, Qu H, Coskun T, Benson C, Haupt A, Kelly RP, O'Farrell L, Sloop KW, Steele JP, Ficorilli J, Regmi A, Rettiganti M, Urva S, Mather KJ, Pratt E. Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies. Mol Metab. 2026 Jan;103:102298. doi: 10.1016/j.molmet.2025.102298. Epub 2025 Dec 12.

Drugs

Indications